UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000051356
Receipt number R000058575
Scientific Title A descriptive study of patients using digital therapeutics for hypertension in real-world
Date of disclosure of the study information 2023/06/16
Last modified on 2023/12/13 15:01:00

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A descriptive study of patients using digital therapeutics for hypertension in real-world

Acronym

A descriptive study of patients using digital therapeutics for hypertension in real-world

Scientific Title

A descriptive study of patients using digital therapeutics for hypertension in real-world

Scientific Title:Acronym

A descriptive study of patients using digital therapeutics for hypertension in real-world

Region

Japan


Condition

Condition

Hypertension

Classification by specialty

Medicine in general Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To explore suitable clinical apply of the DTx for hypertension, patient backgrounds, app usage, and its therapeutic effect based on real-world data will be investigated.

Basic objectives2

Others

Basic objectives -Others

Characteristics of patients

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Characteristics of patients

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients who were prescribed and started using the application between September 1, 2022 and April 30, 2023

Key exclusion criteria

Patients who have indicated to CureApp, Inc. that they refuse to provide information

Target sample size

550


Research contact person

Name of lead principal investigator

1st name Tomoyuki
Middle name
Last name Tanigawa

Organization

CureApp, Inc.

Division name

CureApp, Inc.

Zip code

1030001

Address

4F, 12-5, Nihonbashikodenmacho, Chuo-ku, Tokyo, Japan

TEL

0362310183

Email

tomoyuki.tanigawa@cureapp.jp


Public contact

Name of contact person

1st name Yumi
Middle name
Last name Hirayama

Organization

CureApp, Inc.

Division name

Medical Division

Zip code

1030001

Address

4F, 12-5, Nihonbashikodenmacho, Chuo-ku, Tokyo, Japan

TEL

0362310183

Homepage URL


Email

ht_medical-affairs@cureapp.jp


Sponsor or person

Institute

CureApp, Inc.

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Hillside Clinic Jingumae Ethics Committe

Address

4-22-11 Jingumae, Shibuya-ku, Tokyo

Tel

070-6995-0047

Email

naoki-kitazawa@cmicgroup.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 06 Month 16 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

579

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2023 Year 05 Month 26 Day

Date of IRB

2023 Year 06 Month 07 Day

Anticipated trial start date

2023 Year 06 Month 07 Day

Last follow-up date

2023 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

We will enroll adult hypertensive patients receiving treatment with the digital therapeutics from September 2022 to April 2023.
Patients' backgrounds, including age, gender, weight, and blood pressure and its measurement counts, and other app-usage data will be investigated.


Management information

Registered date

2023 Year 06 Month 16 Day

Last modified on

2023 Year 12 Month 13 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000058575


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name